This issue of Grand Rounds in Urology reviews the current and future use of ADT in treating advanced prostate cancer, but with cost of healthcare an ever growing factor in treatment decisions, it will also examine the potential use of older antiandrogen therapies in treating patients with advanced PCa.




prostate carcinoma, antiandrogens


Medical Editor:

E. David Crawford, MD

Professor of Surgery, Urology, and Radiation Oncology Head, Urologic Oncology

E. David Crawford Endowed Chair in Urologic Oncology

University of Colorado, Denver

Aurora, Colorado



Gerald L. Andriole, Jr., MD

Robert Killian Royce Distinguished Professor

Professor, Surgery Chief, Division of Urologic Surgery

Director, Men’s Health Center

St. Louis, Missouri


Raoul S. Concepcion, MD

Director of Advanced Therapeutics

Urology Associates, Nashville

Nashville, Tennessee


Robert E. Donohue, MD

Professor Emeritus

University of Colorado, Denver

Aurora, Colorado


Leonard G. Gomella, MD

Bernard W. Godwin Jr. Professor of Prostate Cancer

Chairman Department of Urology

Thomas Jefferson University

Philadelphia, Pennsylvania


Daniel P. Petrylak, MD

Director of Genitourinary Oncology

Co-Director, Signal Transduction Program

Yale Cancer Center

New Haven, Connecticut


J. Clifton Vestal, MD


USMD Prostate Cancer Center

USMD Health System

Arlington, Texas




Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001;58(6):1016-20.

Du Plessis DJ. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology. 1991;37(2 Suppl):20-4.

Fisher LD, Gent M, Büller HR. Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. American Heart Journal. 2001;141(1):26–32

Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4.

Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. The Lancet. 1995;346(8970):265–9. [No Authors Listed]

Rothmann M, Li N, Chen G, Chi GYH, Temple R, Tsou H-H. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine. 2002;22(2):239–64.

Schellhammer PF, Sharifi R, Block NL, et al. Nical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology. 1997;50(3):330–6.

Sun M, Choueiri TK, O-P R Hamnvik, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016;2(4):500-7.

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone- Sensitive Prostate Cancer. N Engl J 2015;373:737-46.